Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with newly diagnosed multiple myeloma (NDMM) for whom transplant is not planned as initial therapy: A multicenter, randomized, phase III study (CEPHEUS).
暂无分享,去创建一个
T. Facon | J. Vermeulen | S. Usmani | S. Zweegman | Jianping Wang | M. Krevvata | J. Carey | K. Chastain | E. Smith | Karen Ren